Published: November 2023
On 17 November 2023, Pfizer and Astellas Pharma announced the approval of supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) by the Food and Drug Administration (FDA). The FDA has granted expanded indications for two prominent cancer treatments—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. XTANDI® becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). This approval was supported by the phase III EMBARK trial, demonstrating that XTANDI® in combination with the hormone reducer leuprolide significantly reduced the risk of metastasis or death compared to placebo and leuprolide. Additionally, XTANDI® as a monotherapy achieved a statistically significant reduction in the risk of metastasis or death compared to the same placebo and leuprolide combination as a secondary measure.
This approval signifies a significant advancement, potentially establishing Xtandi as a new standard-of-care option, as highlighted by Shore in a released statement. The FDA expedited Pfizer and Astellas’ application with priority review, fast-track, and real-time oncology designations. Xtandi stands as the sole novel hormone therapy approved for three types of prostate cancer. Sales of Xtandi soared to $5.9 billion in 2022, marking a 27% increase from the previous year.
According to Roots Analysis, the Cancer Therapeutics Market is anticipated to grow at a CAGR of 84% during the forecasted period.
For detailed insights about this domain, check out our report on Cancer Therapeutics Market or email email@example.com
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES